Back to Search
Start Over
SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia
- Source :
- Atherosclerosis, Atherosclerosis, Elsevier, 2020, 306, pp.41-49. ⟨10.1016/j.atherosclerosis.2020.06.011⟩, Atherosclerosis, In press, 306, pp.41-49. ⟨10.1016/j.atherosclerosis.2020.06.011⟩, Atherosclerosis, Elsevier, In press, 306, pp.41-49. ⟨10.1016/j.atherosclerosis.2020.06.011⟩
- Publication Year :
- 2020
- Publisher :
- HAL CCSD, 2020.
-
Abstract
- Background and aims Patients with heterozygous familial hypercholesterolemia (HeFH) present elevated cardiovascular (CV) risk. Current CV risk stratification algorithms developed for the general population are not adapted for heFH patients. It is therefore of singular importance to develop and validate CV prediction tools, which are dedicated to the HeFH population. Methods Our first objective was to validate the Spanish SAFEHEART-risk equation (RE) in the French HeFH cohort (REFERCHOL), and the second to compare SAFEHEART-RE with the low-density-lipoprotein-cholesterol (LDL-C)-year-score for the prediction of CV events in the HeFH French population. Results We included HeFH (n = 1473) patients with a genetic or clinical diagnosis (DLCN score ≥8). Among them, 512 patients with a 5-year follow-up were included to validate the 5 year-CV-RE. A total of 152 events (10.3%) occurred in the entire population of 1473 patients during a mean follow-up of 3.9 years. Over the five-year follow-up, non-fatal CV events occurred in 103 patients (20.2%). Almost all the parameters used in the SAFEHEART-RE were confirmed as strong predictors of CV events in the REFERCHOL cohort. The C-statistic revealed a satisfactory performance of both the SAFEHEART-RE and LDL-C-year-scores in predicting CV events for all the patients (primary and secondary prevention) (C-index 0.77 and 0.70, respectively) as well as for those in primary prevention at inclusion (C-index 0.78 and 0.77, respectively). Conclusions This analysis represents the first external validation of the SAFEHEART-RE and demonstrated that both SAFEHEART-RE and the LDL-C-year-score are good predictors of CV events in primary prevention HeFH patients.
- Subjects :
- cardiovascular risk
0301 basic medicine
medicine.medical_specialty
cardiovascular risk equation
Population
Familial hypercholesterolemia
030204 cardiovascular system & hematology
Risk Assessment
Cohort Studies
Hyperlipoproteinemia Type II
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Internal medicine
medicine
Humans
education
ComputingMilieux_MISCELLANEOUS
Risk equation
[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism
Entire population
education.field_of_study
familial hypercholesterolemia
business.industry
Cholesterol
External validation
Cholesterol, LDL
[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism
medicine.disease
[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
030104 developmental biology
cholesterol-year-score
chemistry
Cardiovascular Diseases
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie
Clinical diagnosis
primary cardiovascular prevention
Cohort
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Cardiology and Cardiovascular Medicine
business
[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
Subjects
Details
- Language :
- English
- ISSN :
- 00219150
- Database :
- OpenAIRE
- Journal :
- Atherosclerosis, Atherosclerosis, Elsevier, 2020, 306, pp.41-49. ⟨10.1016/j.atherosclerosis.2020.06.011⟩, Atherosclerosis, In press, 306, pp.41-49. ⟨10.1016/j.atherosclerosis.2020.06.011⟩, Atherosclerosis, Elsevier, In press, 306, pp.41-49. ⟨10.1016/j.atherosclerosis.2020.06.011⟩
- Accession number :
- edsair.doi.dedup.....030f629f1d32a2b42326b53f919cf792
- Full Text :
- https://doi.org/10.1016/j.atherosclerosis.2020.06.011⟩